Nasopharyngeal Cancer - Pipeline Review, H1 2014


#195083

72pages

Global Markets Direct

$ 2000

In Stock

Nasopharyngeal Cancer - Pipeline Review, H1 2014

Summary

Global Markets Directs, Nasopharyngeal Cancer - Pipeline Review, H1 2014, provides an overview of the Nasopharyngeal Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Nasopharyngeal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nasopharyngeal Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Nasopharyngeal Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Nasopharyngeal Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Nasopharyngeal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Nasopharyngeal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Nasopharyngeal Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Nasopharyngeal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Nasopharyngeal Cancer Overview 7
Therapeutics Development 8
Pipeline Products for Nasopharyngeal Cancer - Overview 8
Pipeline Products for Nasopharyngeal Cancer - Comparative Analysis 9
Nasopharyngeal Cancer - Therapeutics under Development by Companies 10
Nasopharyngeal Cancer - Therapeutics under Investigation by Universities/Institutes 12
Nasopharyngeal Cancer - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Nasopharyngeal Cancer - Products under Development by Companies 17
Nasopharyngeal Cancer - Products under Investigation by Universities/Institutes 18
Nasopharyngeal Cancer - Companies Involved in Therapeutics Development 19
F. Hoffmann-La Roche Ltd. 19
Gilead Sciences, Inc. 20
Merck & Co., Inc. 21
Astex Pharmaceuticals, Inc. 22
Cyclacel Pharmaceuticals Inc. 23
National Cancer Centre Singapore 24
Nasopharyngeal Cancer - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Target 27
Assessment by Mechanism of Action 30
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
nimotuzumab - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
MK-2206 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
CYC-202 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Autologous Epstein-Barr Virus-Specific Cytotoxic T Lymphocytes + [carboplatin]+ [gemcitabine] - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Modified Vaccinia Ankara Vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Cytokine-Induced Killer Cells + [cisplatin] + [gemcitabine] - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Icotinib + [cisplatin] + [paclitaxel] + Radiation Therapy - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
EBV-Specific T-Lymphocytes - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
LMP Specific Cytotoxic T-Lymphocytes - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
HLA Matched Allogeneic Virus Specific Cytotoxic T Lymphocytes - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
EBV-Specific CTL Therapy - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Therapeutic p53 Gene Agent - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
EBV-nRNA - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
AT-13387 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Imidazoles - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
LMP2-TCR Gene Therapy - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
RO-5203280 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Nasopharyngeal Cancer - Recent Pipeline Updates 62
Nasopharyngeal Cancer - Dormant Projects 65
Nasopharyngeal Cancer - Product Development Milestones 66
Featured News & Press Releases 66
Dec 16, 2011: Radiation Therapy Oncology Group Trial Results Show Bevacizumab Reduces Spread Of Nasopharyngeal Cancer 66
May 29, 2009: Cyclacel Reports Initial Phase 2 Seliciclib Data In Patients With Nasopharyngeal Carcinoma At 2009 Asco Annual Meeting 67
Apr 21, 2009: Cyclacel & Dartmouth Researchers Reports Novel Mechanism Of Action For Seliciclib At AACR 67
Mar 05, 2009: Cyclacel Announces Phase 1 Data Elucidating Pharmacodynamics & Mechanism Of Action Of Seliciclib In Nasopharyngeal Cancer 68
Oct 07, 2008: Epstein-Barr Virus Protein Contributes to Cancer 69
Aug 28, 2008: CYCLACEL Announces Recommendations Of Data Review Committee For Seliciclib Phase 2b Non-Small Cell Lung Cancer APPRAISE Trial 69
Jun 28, 2007: Cyclacel Pharmaceuticals Announces Results Of Phase II Seliciclib Combination Studies 70
Appendix 71
Methodology 71
Coverage 71
Secondary Research 71
Primary Research 71
Expert Panel Validation 71
Contact Us 72
Disclaimer 72 List of Tables
Number of Products under Development for Nasopharyngeal Cancer, H1 2014 8
Number of Products under Development for Nasopharyngeal Cancer - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Development, H1 2014 16
Products under Development by Companies, H1 2014 17
Products under Investigation by Universities/Institutes, H1 2014 18
Nasopharyngeal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 19
Nasopharyngeal Cancer - Pipeline by Gilead Sciences, Inc., H1 2014 20
Nasopharyngeal Cancer - Pipeline by Merck & Co., Inc., H1 2014 21
Nasopharyngeal Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2014 22
Nasopharyngeal Cancer - Pipeline by Cyclacel Pharmaceuticals Inc., H1 2014 23
Nasopharyngeal Cancer - Pipeline by National Cancer Centre Singapore, H1 2014 24
Assessment by Monotherapy Products, H1 2014 25
Assessment by Combination Products, H1 2014 26
Number of Products by Stage and Target, H1 2014 29
Number of Products by Stage and Mechanism of Action, H1 2014 32
Number of Products by Stage and Route of Administration, H1 2014 34
Number of Products by Stage and Molecule Type, H1 2014 36
Nasopharyngeal Cancer Therapeutics - Recent Pipeline Updates, H1 2014 62
Nasopharyngeal Cancer - Dormant Projects, H1 2014 65List of Figures
Number of Products under Development for Nasopharyngeal Cancer, H1 2014 8
Number of Products under Development for Nasopharyngeal Cancer - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Products, H1 2014 16
Assessment by Monotherapy Products, H1 2014 25
Assessment by Combination Products, H1 2014 26
Number of Products by Top 10 Target, H1 2014 27
Number of Products by Stage and Top 10 Target, H1 2014 28
Number of Products by Top 10 Mechanism of Action, H1 2014 30
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 31
Number of Products by Top 10 Route of Administration, H1 2014 33
Number of Products by Stage and Top 10 Route of Administration, H1 2014 34
Number of Products by Top 10 Molecule Type, H1 2014 35
Number of Products by Stage and Top 10 Molecule Type, H1 2014 36